| Discipline | |
|---|---|
| Language | English |
| Edited by |
|
| Publication details | |
| History | 2016–present |
| Publisher | Nature Research |
| Frequency | Continuous |
| Open access | Yes |
| Impact factor | 40.8 (2023) |
| Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt  ) | |
| ISO 4 | Signal Transduct. Target. Ther. |
| Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus | |
| ISSN | 2095-9907 (print) 2059-3635 (web) |
| LCCN | 2016243461 |
| OCLC no. | 1026877558 |
| Links | |
Signal Transduction and Targeted Therapy is a multidisciplinary peer-reviewed open access scientific journal covering biomedical research with a particular focus on signal transduction and its application to the drug development process. It was established in 2016 and is published by Nature Research. The editors-in-chief are Carlo M. Croce (Ohio State University), Kang Zhang (Macau University of Science and Technology), and Yu-Quan Wei (West China Medical Center). According to the Journal Citation Reports, the journal has a 2023 impact factor of 40.8.
References
- "Signal Transduction and Targeted Therapy". 2023 Journal Citation Reports. Web of Science (Science ed.). Clarivate Analytics. 2023.
  | This article about a pharmacology journal is a stub. You can help Misplaced Pages by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |